EA202190193A1 - Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы - Google Patents
Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазыInfo
- Publication number
- EA202190193A1 EA202190193A1 EA202190193A EA202190193A EA202190193A1 EA 202190193 A1 EA202190193 A1 EA 202190193A1 EA 202190193 A EA202190193 A EA 202190193A EA 202190193 A EA202190193 A EA 202190193A EA 202190193 A1 EA202190193 A1 EA 202190193A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- alkoxypyrazoles
- activators
- guanylate cyclase
- soluble guanylate
- diseases
- Prior art date
Links
- 102000007637 Soluble Guanylyl Cyclase Human genes 0.000 title 1
- 108010007205 Soluble Guanylyl Cyclase Proteins 0.000 title 1
- 239000012190 activator Substances 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 2
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 230000007882 cirrhosis Effects 0.000 abstract 1
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- 208000007232 portal hypertension Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862696887P | 2018-07-12 | 2018-07-12 | |
| PCT/EP2019/068448 WO2020011804A1 (en) | 2018-07-12 | 2019-07-09 | Alkoxy pyrazoles as soluble guanylate cyclase activators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202190193A1 true EA202190193A1 (ru) | 2021-06-16 |
Family
ID=67314737
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202190193A EA202190193A1 (ru) | 2018-07-12 | 2019-07-09 | Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11690848B2 (enExample) |
| EP (1) | EP3820470B1 (enExample) |
| JP (2) | JP2021530488A (enExample) |
| KR (1) | KR20210032443A (enExample) |
| CN (1) | CN112384214A (enExample) |
| AU (1) | AU2019301887A1 (enExample) |
| BR (1) | BR112020025670A2 (enExample) |
| CA (1) | CA3103727A1 (enExample) |
| CL (1) | CL2021000023A1 (enExample) |
| EA (1) | EA202190193A1 (enExample) |
| MA (1) | MA53118A (enExample) |
| MX (1) | MX2021000405A (enExample) |
| PH (1) | PH12021550075A1 (enExample) |
| WO (1) | WO2020011804A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4496571A1 (en) * | 2022-03-21 | 2025-01-29 | Boehringer Ingelheim International GmbH | Soluble guanylate cyclase activators for treating portal hypertension |
| CN120225203A (zh) * | 2022-11-04 | 2025-06-27 | 勃林格殷格翰国际有限公司 | 用于治疗系统性硬化症的可溶性鸟苷酸环化酶活化剂 |
| WO2024123847A1 (en) | 2022-12-09 | 2024-06-13 | Boehringer Ingelheim International Gmbh | Solid forms of a sgc activator |
| CN121620369A (zh) * | 2023-08-16 | 2026-03-06 | 勃林格殷格翰国际有限公司 | 用于治疗临床显著门静脉高压和失代偿期肝硬化的可溶性鸟苷酸环化酶激活剂 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20191755T1 (hr) | 2012-09-07 | 2019-12-27 | Boehringer Ingelheim International Gmbh | Alkoksipirazoli kao aktivatori topljive gvanilat ciklaze |
| AU2017216429B2 (en) * | 2016-02-01 | 2022-10-06 | Cyclerion Therapeutics, Inc. | Use of sGC stimulators for the treatment of Nonalcoholic Steatohepatitis (NASH) |
| EP3458063A4 (en) * | 2016-05-18 | 2020-02-26 | Merck Sharp & Dohme Corp. | METHOD FOR USE OF TRIAZOLO-PYRAZINYL-SOLUBLE GUANYLATE CYCLASE ACTIVATORS IN FIBROTIC DISEASES |
-
2019
- 2019-07-09 WO PCT/EP2019/068448 patent/WO2020011804A1/en not_active Ceased
- 2019-07-09 JP JP2021500613A patent/JP2021530488A/ja active Pending
- 2019-07-09 BR BR112020025670-6A patent/BR112020025670A2/pt not_active IP Right Cessation
- 2019-07-09 AU AU2019301887A patent/AU2019301887A1/en not_active Abandoned
- 2019-07-09 KR KR1020217004281A patent/KR20210032443A/ko not_active Ceased
- 2019-07-09 US US17/258,759 patent/US11690848B2/en active Active
- 2019-07-09 EP EP19740509.5A patent/EP3820470B1/en active Active
- 2019-07-09 EA EA202190193A patent/EA202190193A1/ru unknown
- 2019-07-09 CN CN201980045881.XA patent/CN112384214A/zh active Pending
- 2019-07-09 CA CA3103727A patent/CA3103727A1/en active Pending
- 2019-07-09 MA MA053118A patent/MA53118A/fr unknown
- 2019-07-09 MX MX2021000405A patent/MX2021000405A/es unknown
-
2021
- 2021-01-06 CL CL2021000023A patent/CL2021000023A1/es unknown
- 2021-01-12 PH PH12021550075A patent/PH12021550075A1/en unknown
-
2024
- 2024-03-27 JP JP2024052193A patent/JP2024095711A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024095711A (ja) | 2024-07-10 |
| JP2021530488A (ja) | 2021-11-11 |
| PH12021550075A1 (en) | 2021-09-20 |
| AU2019301887A1 (en) | 2021-01-07 |
| EP3820470A1 (en) | 2021-05-19 |
| CA3103727A1 (en) | 2020-01-16 |
| WO2020011804A1 (en) | 2020-01-16 |
| BR112020025670A2 (pt) | 2021-03-16 |
| CN112384214A (zh) | 2021-02-19 |
| EP3820470B1 (en) | 2024-09-11 |
| KR20210032443A (ko) | 2021-03-24 |
| US20210121473A1 (en) | 2021-04-29 |
| MA53118A (fr) | 2021-05-19 |
| US11690848B2 (en) | 2023-07-04 |
| CL2021000023A1 (es) | 2021-06-11 |
| MX2021000405A (es) | 2021-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202190193A1 (ru) | Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы | |
| EA201991894A1 (ru) | ПИПЕРИДИН-ЗАМЕЩЕННЫЕ ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ | |
| EA202190630A1 (ru) | Способы комбинированной терапии | |
| EA201691401A1 (ru) | Индазольные соединения в качестве ингибиторов irak4 | |
| GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
| EA201790078A1 (ru) | Ингибиторы mnk и связанные с ними способы | |
| EA201991399A1 (ru) | Аминотриазолопиридиновые соединения и их применение в лечении рака | |
| EA202193015A1 (ru) | Ингибиторы cdk | |
| EA201692267A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
| EA201270043A1 (ru) | Замещенные производные изоиндолин-1,3-диона | |
| EA201692249A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
| EA201692268A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
| MA37712B1 (fr) | Inhibiteurs macrocycliques de virus flaviviridae | |
| EA201592020A1 (ru) | Новая композиция для неалкогольной жировой болезни печени (нажбп) | |
| EA201692266A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
| EA201790779A1 (ru) | Замещенные аминопуриновые соединения, их композиции и способы лечения с использованием таких соединений | |
| EA202190464A1 (ru) | Замещенные бензимидазолы в качестве ингибиторов pad4 | |
| EA201692260A1 (ru) | Соединения 1,3,4-тиадиазола и их применение в лечении рака | |
| MX2021002305A (es) | Tratamiento de trastornos del higado. | |
| EA201691342A1 (ru) | Пиразолоновые соединения и их применение | |
| EA202190776A1 (ru) | Комбинация маломолекулярных ингибиторов cd-47 с другими противораковыми агентами | |
| EA201692470A1 (ru) | Фармацевтические комбинации | |
| JOP20170108A1 (ar) | مثبطات معزز نظير zeste 2 | |
| EA201692481A1 (ru) | Комбинация, содержащая глюкокортикоид и edo-s101 | |
| EA202091804A1 (ru) | Гетероциклил-замещенные оксадиазолопиридиновые производные для применения в качестве ингибиторов грелин-о-ацилтрансферазы (goat) |